RxDoctor Payments Data

Tonya Youngblood, MD

Family Medicine · Pittsburg, TXNPI 1295701969

Payments from drug & device makers

$991in general payments, 2019–2025

Across 61 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$186
  • AbbVie$132
  • AstraZeneca$118
  • Exact Sciences$99
  • Lilly USA, LLC$72
  • Amgen$65
  • plus $319 from 10 others

What the payments were for

  • Food & beverage$991100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$991 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$11,815
Medicare patients
51
Services billed
921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide220$218,556
MounjaroTirzepatide89$102,499
EliquisApixaban87$82,711
JardianceEmpagliflozin108$81,644
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$57,929
JanuviaSitagliptin Phosphate43$45,596
LinzessLinaclotide32$26,511
TrulicityDulaglutide16$22,505
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$19,447
FarxigaDapagliflozin Propanediol24$17,205
Lantus SolostarInsulin Glargine,hum.Rec.Anlog101$15,299
RybelsusSemaglutide15$15,099
XareltoRivaroxaban13$10,914
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$9,845
Aimovig AutoinjectorErenumab-Aooe12$9,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$186$233,655235 claims
Lilly USA, LLCMounjaro, Trulicity$72$125,005105 claims
PfizerEliquis$32$82,71187 claims
GSKTrelegy Ellipta, Breo Ellipta$16$64,63781 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$118$33,81672 claims
AbbVieLinzess, Synthroid$132$29,71779 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Pittsburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →